Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMA 901

Drug Profile

IMA 901

Alternative Names: IMA-901; Renal cancer vaccine - immatics

Latest Information Update: 23 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator immatics biotechnologies GmbH
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Renal cell carcinoma

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 17 Aug 2015 immatics Biotechnologies completes a phase III trial in Renal cell carcinoma (First-line therapy, Combination therapy, Late-stage disease) in France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Romania, Russia, USA and United Kingdom (NCT01265901)
  • 21 Apr 2015 Phase-III development for Renal cell carcinoma (Combination therapy, First-line therapy, Late-stage disease) is ongoing in France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Romania, Russia, USA and United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top